Compare OPRX & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPRX | ALXO |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | 105 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.1M | 172.8M |
| IPO Year | 2008 | 2020 |
| Metric | OPRX | ALXO |
|---|---|---|
| Price | $7.68 | $1.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $12.30 | $4.60 |
| AVG Volume (30 Days) | 181.3K | ★ 1.3M |
| Earning Date | 11-11-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 124.55 | 26.36 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $109,429,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.01 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.78 | N/A |
| 52 Week Low | $4.54 | $0.86 |
| 52 Week High | $15.59 | $2.66 |
| Indicator | OPRX | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 37.22 | 42.28 |
| Support Level | $7.23 | $1.03 |
| Resistance Level | $8.30 | $1.34 |
| Average True Range (ATR) | 0.69 | 0.15 |
| MACD | -0.19 | -0.00 |
| Stochastic Oscillator | 38.21 | 27.42 |
OptimizeRx Corp is engaged in the healthcare market in the United States. is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. OptimizeRx helps life sciences organizations engage and support their customers through its combined HCP and DTC marketing strategies.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.